Mechanisms of action and clinical characteristics of three atypical antidepressants: Venlafaxine, nefazodone, bupropion

Journal of Affective Disorders

Volumn 51, Issue 3, 1998, Pages 237-254

  Horst, W Dale ^a   Preskorn, Sheldon H ^b  

^a University of Kansas School of Medicine Wichita Psychiatric Research Institute   (United States)

^b UNIVERSITY OF KANSAS SCHOOL OF MEDICINE WICHITA   (United States)

Author keywords

Antidepressants; Bupropion; Nefazodone; Venlafaxine

Indexed keywords

ALPHA ADRENERGIC RECEPTOR; AMFEBUTAMONE; ANTIDEPRESSANT AGENT; CHOLINERGIC RECEPTOR; DESIPRAMINE; FLUOXETINE; HISTAMINE RECEPTOR; IMIPRAMINE; NEFAZODONE; SEROTONIN RECEPTOR; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRICYCLIC ANTIDEPRESSANT AGENT; VENLAFAXINE;

ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DRUG EFFICACY; DRUG HALF LIFE; DRUG INHIBITION; DRUG MECHANISM; DRUG METABOLISM; DRUG RECEPTOR BINDING; DRUG TOLERANCE; FATIGUE; GASTROINTESTINAL SYMPTOM; HUMAN; NEUROLOGIC DISEASE; NONHUMAN; PRIORITY JOURNAL; RASH; URINARY TRACT DISEASE; VISUAL DISORDER;

ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; BUPROPION; CYCLOHEXANOLS; DEPRESSIVE DISORDER; HUMANS; TRIAZOLES;

EID: 0032428903     PISSN: 01650327     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0165-0327(98)00222-5     Document Type: Article

References (97)

1. Anonymous, 1993a. Venlafaxine presentation to the Food and Drag Administration Psychopharmacology Advisory Committee.
2. Anonymous, 1993b. Nefazodone safety update No. 2: integrated summary of safety information. Bristol-Myers Squibb Company.
3. Armitage, R., Roffwarg, H.P., Cain, J., Trivedi, M., Rush, A.J., 1993. The effect of nefazodone on ultradian rhythms in EEG frequencies in major depression. Sleep Res. 22, 32.
4. Ascher, J.A., Cole, J.O., Colin, J.-N., Feighner, J.P., Ferris, R.M., Fibiger, H.C., Golden, R.N., Martin, P., Potter, W.Z., Richelson, E., Sulser, F., 1995. Bupropion: A review of its mechanism of antidepressant activity. J. Clin. Psychiatry 56, 395-401.
5. Baron, B.M., Ogden, A., Siegel, B.W., Stegeman, J., Ursillo, R.C., Dudley, M.W., 1988. Rapid down regulation of β-adrenoceptors by co-administration of desipramine and fluoxetine. Eur. J. Pharmacol. 154, 125-134.
6. Bolden-Watson, C., Richelson, E., 1993. Blockade by newly-developed antidepressants of biogenic amine uptake into rat brain synaptosomes. Life Sci. 52, 1023-1029.
7. Brown, W.A., Bornseif, B.E., Wernicke, J.F., 1988. Placebo response in depression: a search for predictors. Psychiatry Res. 26, 259-264.
8. Burke, M.J., Silkey, B., Preskorn, S.H., 1994. Pharmacoeconomic considerations when evaluating treatment options for major depressive disorder. J. Clin. Psychiatry 55, 42-52.
9. Caccia, S., Ballabio, M., Samanin, R., Zanini, M.G., Garattini, S., 1981. (-)-m-Chlorophenyl-piperazine, a central 5-hydroxytryptamine agonist, is a metabolite of trazodone. J. Pharm. Pharmacol. 33, 477-478.
10. Clerc, G.E., Ruimy, P., Verdeau-Pailles, J., 1994. A double-blind comparison of venlafaxine and fluoxetine in patients hospitalized for major depression and melancholia. Int. Clin. Psychopharmacol. 9, 139-143.
11. Cooper, B.R., Hester, T.J., Maxwell, R.A., 1990. Behavioral and biochemical effects of the antidepressant bupropion (Wellbutrin): evidence for selective blockade of dopamine uptake in vivo. J. Pharmacol. Exp. Ther. 215, 127-134.
12. Cooper, B.R., Wang, C.M., Cox, R.F., Norton, R., Shea, V., Ferris, R.M., 1994. Evidence that the acute behavioral and electrophysiological effects of bupropion (Wellbutrin) are mediated by noradrenergic mechanism. Neuropsychopharmacology 11, 133-141.
13. Cusack, B., Nelson, A., Richelson, E., 1994. Binding of antidepressants to human brain receptors: focus on newer generation compounds. Psychopharmacology 114, 559-565.
14. D'Amico, M.F., Roberts, D.L., Robinson, D.S., Schwiderski, U.E., Copp, J., 1990. Placebo-controlled dose ranging trial designs in Phase II development of nefazodone. Psychopharmacol. Bull. 26, 147-150.
15. Davidson, J., 1989. Seizures and bupropion: a review. J. Clin. Psychiatry 50, 256-261.
16. Eison, A.S., Eison, M.S., Torrente, J.R., Wright, R.N., Yocca, F.D., 1990. Nefazodone: preclinical pharmacology of a new antidepressant. Psychopharmacol. Bull. 26, 311-315.
17. Fabre, L., Brodie, H.K.H., Garver, D., Zung, W.W., 1983. A multicenter evaluation of bupropion versus placebo in hospitalized depressed patients. J. Clin. Psychiatry 44, 88-94.
18. Fabre, L.F., McLendon, D.M., 1978. Double-blind placebo-controlled study of bupropion hydrochloride (Wellbutrin) in the treatment of depressed inpatients. Curr. Ther. Res. 23, 393-402.
19. Fawcett, J., Marcus, R.N., Anton, S.F., O'Brien, K., Schwiderski, U., 1995. Response of anxiety and agitation symptoms during nefazodone treatment of major depression. J. Clin. Psychiatry 56, 37-42.
20. Feighner, J.P., Pambakian, R., Fowler, R.C., Boyer, W.F., D'Amico, M.F., 1989. A comparison of nefazodone, imipramine, and placebo in patients with moderate to severe depression. Psychopharmacol. Bull. 25, 219-221.
21. Feighner, J.P., 1994. The role of venlafaxine in rational antidepressant therapy. J. Clin. Psychiatry 55, 62-68.
22. Ferris, R.M., White, H.L., Cooper, B.R., 1981. Some neurochemical properties of a new antidepressant, bupropion hydrochloride (Wellbutrin). Drug Dev. Res. 1, 21-35.
23. Ferris, R.M., Cooper, B.R., 1993. Mechanism of antidepressant activity of bupropion. J. Clin. Psychiatry Monograph. 11, 2-14.
24. Fontaine, R., Ontiveros, A., Elie, R., Kensler, T.T., Roberts, D.L., Kaplita, S., Ecker, J.A., Faludi, G., 1994. A double-blind comparison of nefazodone, imipramine, and placebo in major depression. J. Clin. Psychiatry 55, 234-241.
25. Franc, J.E., Duncan, G.F., Farmen, R.H., Pittman, K.A., 1991. High-performance liquid chromatographic method for the determination of nefazodone and its metabolites in human plasma using laboratory robotics. J. Chromatogr. 570, 129-138.
26. Frazer, A., Brown, R., Kocsis, J., Caroff, S., Amsterdam, J., Winokur, A., Sweeney, J., Stokes, P., 1986. Patterns of melatonin rhythms in depression. J. Neural. Transm. Suppl. 21, 269-290.
27. Gaillard, J.M., Nicholson, A.N., Pascoe, P.A., 1989. Neurotransmitter systems. In: Kryger, M.H., et al. (Eds.), Principles and Practice of Sleep Medicine. WB Saunders, Philadelphia, PA.
28. Goldberg, H.L., Finnerty, R., 1988. An open-label, variable-dose study of WY-45,030 (venlafexine) in depressed outpatients. Psychopharmacol. Bull. 24, 198-199.
29. Golden, R.N., DeVane, C.L., Laizure, S.C., Rudorfer, M.V., Sherer, M.A., Potter, W.Z., 1988. Bupropion in depression. II. The role of metabolites in clinical outcome. Arch. Gen. Psychiatry 45, 145-149.
30. Golden, R.N., Markey, S.P., Risby, E.D., Rudorfer, M.V., Cowdry, R.W., Potter, W.Z., 1988. Antidepressants reduce whole-body norepinephrine turnover while enhancing 6-hydroxymelatonin output. Arch. Gen. Psychiatry 45, 150-154.
31. Golden, R.N., Rudorfer, M.V., Sherer, M.A., Linnoila, M., Potter, W.Z., 1988. Bupropion in depression. I. Biochemcial effects and clinical response. Arch. Gen. Psychiatry 45, 139-143.
32. Grunder, G., Wetzel, H., Schlober, R., Benkert, O., 1996. Subchronic antidepressant treatment with venlafaxine or imipramine and effects on blood pressure and heart rate: assessment by automatic 24-hour monitoring. Pharmacopsychiatry 29, 72-78.
33. Guelfi, J.D., White, C., Magni, G., 1992. A randomized, double-blind comparison of venlafaxine and placebo in inpatients with major depression and melancholia. Clin. Neuropharmacol. 15, 323B.
34. Guelfi, J.D., White, C., Hackett, D., Guichoux, J.Y., Magni, G., 1995. Effectiveness of venlafaxine in patients hospitalized for major depression and melancholia. J. Clin. Psychiatry 56, 450-458.
35. Halaris, A.E., Stern, W., Van Wyck-Fleet, J., Reno, R.N., 1983. Evaluation of the safety and efficacy of bupropion in depression. J. Clin. Psychiatry 44, 101-103.
36. Harvey, A.T., Preskorn, S.H., 1997. Mechanism of action of venlafaxine in normal male volunteers. Clin. Pharmacol. Ther. 61, 175.
37. Haskins, J.T., Moyer, J.A., Muth, E.A., Sigg, E.B., 1985. DMI, Wy-45,030, Wy-45,881 and ciramadol inhibit locus coeruleus neuronal activity. Eur. J. Pharmacol. 115, 139-146.
38. Hemrick-Luecke, S.K., Snoddy, H.D., Fuller, R.W., 1994. Evaluation of nefazodone as a serotonin uptake inhibitor and a serotonin antagonist in vivo. Life Sci. 55, 479-483.
39. Holliday, S.M., Benfield, P., 1995. Venlafaxine: a review of its pharmacology and therapeutic potential in depression. Drugs 49, 280-294.
40. Joffe, R.T., Levitt, A.J., Sokolov, S.T.H., Young, L.T., 1996. Response to an open trial of a second SSRI in major depression. J. Clin. Psychiatry 57, 114-115.
41. Kahn, R.S., Asnis, G.M., Wetzler, S., van Praag, H.M., 1988. Neuroendocrine evidence for serotonin receptor hypersensitivity in panic disorder. Psychopharmacology 96, 360-364.
42. Khan, A., Fabre, L.F., Rudolph, R., 1991. Venlafaxine in depressed outpatients. Psychopharmacol. Bull. 27, 141-144.
43. Klamerus, K.J., Maloney, K., Rudolph, R.L., Sisenwine, S.F., Jusko, W.J., Chiang, S.T., 1992. Introduction of a composite parameter to the pharmacokinetics of venlafaxine and its active O-desmethyl metabolite. J. Clin. Pharmacol. 32, 716-724.
44. Lader, M.H., 1996. Tolerability and safety: essentials in antidepressant pharmacotherapy. J. Clin. Psychiatry 57, 39-44.
45. Laizure, S.C., DeVane, C.L., Stewart, J.T., Dommisse, C.S., Lai, A.A., 1985. Pharmacokinetics of bupropion and its major basic metabolites in normal subjects after a single dose. Clin. Pharmacol. Ther. 38, 586-589.
46. Leonard, B.E., 1996. New approaches to the treatment of depression. J. Clin. Psychiatry 57, 26-33.
47. Martin, P., Massol, J., Colin, J.N., Lacomblez, L., Puech, A.J., 1990. Antidepressant profile of bupropion and three metabolites in mice. Pharmacopsychiatry 23, 187-194.
48. Mayol, R.F., Cole, C.A., Luke, G.M., Colson, K.L., Kerns, E.H., 1994. Characterization of the metabolites of the antidepressant drug nefazodone in human urine and plasma. Drug Metab. Dispos. 22, 304-311.
49. Meltzer, H.Y., 1991. Beyond serotonin. J. Clin. Psychiatry 52, 58-62.
50. Mendels, J., Johnston, R., Mattes, J., Riesenberg, R., 1993. Efficacy and safety of b.i.d. doses of venlafaxine in a dose-response study. Psychopharmacol. Bull. 29, 169-174.
51. Mendels, J., Reimherr, F., Marcus, R.N., Roberts, D.L., Francis, R.J., Anton, S.F., 1995. A double-blind, placebo-controlled trial of two dose ranges of nefazodone in the treatment of depressed outpatients. J. Clin. Psychiatry 56, 30-36.
52. Mendlewicz, J., 1995. Pharmacologic profile and efficacy of venlafaxine. Int. Clin. Psychopharmacol. 10, 5-13.
53. Monteleone, P., Maj, M., Iovino, M., Steardo, L., 1990. GABA, depression and the mechanism of action of antidepressant drugs: a neuroendocrine approach. J. Affect. Disord. 20, 1-5.
54. Muth, E.A., Haskins, J.T., Moyer, J.A., Husbands, G.E.M., Nielsen, S.T., Sigg, E.B., 1986a. Antidepressant biochemical profile of the novel bicyclic compound Wy-45,030, an ethyl cyclohexanol derivative. Biochem. Pharmacol. 35, 4493-4497.
55. Muth, E.A., Moyer, J.A., Andree, T.H., 1986b. A pharmacological profile of Wy-45,233, the major metabolite in humans of the novel bicyclic antidepressant candidate, Wy-45,030. Soc. Neurosci. 12, 473.
56. Muth, E.A., Moyer, J.A., Haskins, J.T., Andree, T.H., Husbands, G.E.M., 1991. Biochemical, neurophysiological, and behavioral effects of Wy-45,233 and other identified metabolites of the antidepressant venlafaxine. Drug Dev. Res. 23, 191-199.
57. Nelson, J.C., Mazure, C.M., Bowers, M.B., Jatlow, P.I., 1991. A preliminary, open study of the combination of fluoxetine and desipramine for rapid treatment of major depression. Arch. Gen. Psychiatry 48, 303-307.
58. Nierenberg, A.A., Feighner, J.P., Rudolph, R., Cole, J.O., Sullivan, J., 1994. Venlafaxine for treatment-resistant unipolar depression. J. Clin. Psychopharmacol. 14, 419-423.
59. Nofzinger, E.A., Reynolds III, C.F., Thase, M.E., Frank, E., Jennings, J.R., Fasiczka, A.L., Sullivan, L.R., Kupfer, D.J., 1995. REM sleep enhancement by bupropion in depressed men. Am. J. Psychiatry 152, 274-276.
60. Nomikos, G.G., Damsma, G., Wenkstern, D., Fibiger, H.C., 1992. Effects of chronic bupropion on interstitial concentrations of dopamine in rat nucleus accumbens and striatum. Neuropsychopharmacology 7, 7-14.
61. Owens, M.J., Ieni, J.R., Knight, D.L., Winders, K., Nemeroff, C.B., 1995. The serotonerigic antidepressant nefazodone inhibits the serotonin transporter: in vivo and ex vivo studies. Life Sci. 57, 373-380.
62. Peck, A.W., Stern, W.C., Watkinson, C., 1983. Incidence of seizures during treatment with tricyclic antidepressant drugs and bupropion. J. Clin. Psychiatry 44, 197-201.
63. Peroutka, S.J., Snyder, S.H., 1980. Long-term antidepressant treatment decreases spiroperidol-labeled serotonin receptor binding. Science 210, 88-90.
64. Perumal, A.S., Smith, T.M., Suckow, R.F., Cooper, T.B., 1986. Down regulation of β-receptors by bupropion and its major metabolite in mouse brain. Neuropsychopharmacology 25, 1323-1326.
65. Pitts, W.M., Fann, W.E., Halaris, A., Dressler, D.M., Sajadi, C., Snyder, S., Ilaria, R.L., 1983. Bupropion in depression: a tri-center placebo controlled study. J. Clin. Psychiatry 44, 95-100.
66. Preskorn, S.H., 1983. Antidepressant response and plasma concentrations of bupropion. J. Clin. Psychiatry 44, 137-139.
67. Preskorn, S.H., 1991. Should bupropion dosage be adjusted based upon therapeutic drug monitoring? Psychopharmacol. Bull. 27, 637-643.
68. Preskorn, S.H., 1994. Antidepressant drug selection: criteria and options. J. Clin. Psychiatry 55, 6-22.
69. Preskorn, S.H., 1995a. Should rational drug development in psychiatry target more than one mechanism of action in a single molecule? Int. Rev. Psychiatry 7, 17-28.
70. Preskorn, S.H., 1995b. Comparison of the tolerability of bupropion, fluoxetine, imipramine, nefazodone, paroxetine, sertraline, and venlafaxine. J. Clin. Psychiatry 56, 12-21.
71. Preskorn, S.H., 1995c. Comparison of the tolerability of nefazodone, imipramine, fluoxetine, sertraline, paroxetine, and venlafaxine. J. Clin. Psychiatry 56, 17-25.
72. Preskorn, S.H., Janicak, P.G., Davis, J.M., Ayd, F.J., Janicak, P.G., 1995. Advances in the pharmacotherapy of depressive disorders. Principles and Practice of Psychopharmacotherapy, 0-683-05841-X. Baltimore: Williams & Wilkins, p. 1.
73. Preskorn, S.H., Burke, M., 1992. Somatic therapy for major depressive disorder: selection of an antidepressant. J. Clin. Psychiatry 53, 5-18.
74. Preskorn, S.H., Katz, S.E., 1989. Bupropion plasma levels: intraindividual and interindividual variability. Ann. Clin. Psychiatry 1, 59-61.
75. Preskorn, S.H., Othmer, S.C., 1984. Evaluation of bupropion hydrochloride: the first of a new class of atypical antidepressants. Pharmacotherapy 4, 20-34.
76. Richelson, E., 1994. Pharmacology of antidepressants - characteristics of the ideal drug. Mayo Clin. Proc. 69, 1069-1081.
77. Rickels, K., Schweizer, E., Clary, C., Fox, I., Weise, C., 1994. Nefazodone and imipramine in major depression: a placebo-controlled trial. Br. J. Psychiatry 164, 802-805.
78. Robinson, D.S., Marcus, R.N., Archibald, D.G., Hardy, S.A., 1996. Therapeutic dose range of nefazodone in the treatment of major depression. J. Clin. Psychiatry 57, 6-9.
79. Salazar, D.E., Chaikin, P.C., Swanson, B.N., Raymond, R.H., 1995. The effects of nefazodone and fluoxetine on platelet serotonin uptake and whole blood serotonin. Clin. Pharmacol. Ther. 55, 137.
80. Schroeder, D.H., 1983. Metabolism and kinetics of bupropion. J. Clin. Psychiatry 44, 79-81.
81. Schweizer, E., Clary, C., Weise, C., Rickels, K., 1988. An open-label, dose-finding study of WY-45,030, a novel bicyclic antidepressant. Psychopharmacol. Bull. 24, 195-197.
82. Schweizer, E., Weise, C., Clary, C., Fox, I., Rickels, K., 1991. Placebo-controlled trial of venlafaxine for the treatment of major depression. J. Clin. Psychopharmacol. 11, 233-236.
83. Sharpley, A.L., Walsh, A.E., Cowen, P.J., 1992. Nefazodone - a novel antidepressant - may increase REM sleep. Biol. Psychiatry 31, 1070-1073.
84. Stern, W.C., Harto-Truax, B.S., 1980. Two multicenter studies of the antidepressant effects of bupropion HCl versus placebo. Psychopharmacol. Bull. 16, 43-46.
85. Taylor, D.P., Becker, J.A., Crane, M., Hyslop, D.K., Riblet, L.A., Temple, D.L., 1983. Chronic treatment with buspirone reduces type two serotonin binding sites. Soc. Neurosci. Abst. 9, 435.
86. Taylor, D.P., Smith, D.W., Hyslop, D.K., Riblet, L.A., Temple, D.L., Jr., 1986. Receptor binding and atypical antidepressant drug discovery. In: O'Brien, R.A. (Ed.), Receptor Binding and Drug Research. Harcel Dekker, New York, pp. 151-165.
87. Taylor, D.P., Carter, R.B., Eison, A.S., Mullins, U.L., Smith, H.L., Torrente, J.R., Wright, R.N., Yocca, F.D., 1995. Pharmacology and neurochemistry of nefazodone, a novel antidepressant drug. J. Clin. Psychiatry 56, 3-11.
88. Troy, S.M., Parker, V.D., Fruncillo, R.J., Chiang, S.T., 1995. The pharmacokinetics of venlafaxine when given in a twice-daily regimen. J. Clin. Pharmacol. 35, 404-409.
89. Van der Maelen, C.P., Wilderman, R.C., 1984. Iontrophoretic and systemic administration of the non-benzodiazepine anxiolytic drag buspirone causes inhibition of serotonergic dorsal rapne neurons in rats. Fed. Proc. 43, 947.
90. Vogel, G., 1989. Sleep variables and the treatment of depression. In: Kryger, M.H., et al. (Eds.), Principles and Practices of Sleep Medicine. WB Saunders, Philadelphia, PA.
91. Ware, J.C., McBrayer, R., Rose, V., 1993. REM sleep enhancement by nefazodone, trazodone, and buspirone. Sleep Res. 22, 51.
92. Wenger, T.L., Cohn, J.B., Bustrack, J., 1983. Comparison of the effects of bupropion and amitriptyline on cardiac conduction in depressed patients. J. Clin. Psychiatry 44, 174-175.
93. Zajecka, J.M., 1996. The effect of nefazodone on comorbid anxiety symptoms associated with depression: experience in family practice and psychiatric outpatient settings. J. Clin. Psychiatry 57, 10-14.
94. Zarate, C.A., Kando, J.C., Tohen, M., Weiss, M.K., Cole, J.O., 1996. Does intolerance or lack of response with fluoxetine predict the same will happen with sertraline? J. Clin. Psychiatry 57, 67-71.
95. Zarrindast, M.-R., Abolfathi-Araghi, F., 1992. Effects of bupropion on core body temperature of mice. Psychopharmacology 106, 248-252.
96. Zarrindast, M.-R., Minaian, A., 1991. Different effects of direct and indirect dopamine receptor agonists on immobility time in reserpine-treated mice. Gen. Pharm. 22, 1017-1021.
97. Zung, W.W., Brodie, H.K., Fabre, L., McLendon, D., Garver, D., 1983. Comparative efficacy and safety of bupropion and placebo in the treatment of depression. Psychopharmacology-Berl. 79, 343-347.